Inhibrx Biosciences (INBX) Operating Leases (2023 - 2026)

Inhibrx Biosciences (INBX) has reported Operating Leases for 3 consecutive years, with $4.1 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Operating Leases fell 48.72% year-over-year to $4.1 million; the TTM figure through Dec 2025 stood at $4.1 million (down 48.72% YoY), while the FY2025 annual figure was $4.1 million, down 48.72% from the prior year.
• Operating Leases slipped to $4.1 million in Q4 2025 per INBX's latest filing, from $7.0 million in the prior quarter.
• Across five years, Operating Leases topped out at $8.0 million in Q4 2024 and bottomed at $1.1 million in Q4 2023.
• Historically, Operating Leases has averaged $4.7 million across 3 years, with a median of $5.0 million in 2025.
• Annual changes were most pronounced in 2024 — Operating Leases soared 625.05% — and 2025, when it sank 48.72%.
• Inhibrx Biosciences' Operating Leases stood at $1.1 million in 2023, then jumped by 625.05% to $8.0 million in 2024, then sank by 48.72% to $4.1 million in 2025.
• Business Quant data shows INBX's Operating Leases at $4.1 million in Q4 2025, $7.0 million in Q3 2025, and $7.5 million in Q2 2025.